Outset Medical
Post in 2025
Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.
Mendaera is a medtech startup specializing in advanced healthcare technologies, focusing on robotics and diagnostic tools. Its platform integrates robotics, AI, real-time imaging, and connectivity to enable consistent medical interventions at scale, aiming to make high-quality care accessible to all patients.
Caresyntax
Series C in 2024
Caresyntax develops a digital surgery platform that improves patient outcomes by analyzing large volumes of data from operating rooms. Its proprietary software and AI enable OR teams to predict and enhance surgical performance, helping surgeons benchmark their care, hospital administrators optimize resources, medical device companies advance products, and insurance providers assess risk.
Tenaya Therapeutics
Post in 2024
Tenaya Therapeutics is a preclinical stage biotechnology company based in South San Francisco, California, specializing in the development of innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs a multipronged approach to address the fundamental cellular pathologies associated with cardiac muscle disease. Tenaya Therapeutics advances its product candidates through three primary platforms: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads to cardiac fibroblasts, and a precision medicine platform that offers personalized treatment strategies. Through its research, the company aims to enable physicians to regenerate heart tissue and tackle various forms of cardiomyopathies effectively.
COMPASS Pathways
Post in 2023
COMPASS Pathways is a UK-based mental health care company dedicated to accelerating patient access to innovative treatments for mental health challenges. The company focuses on developing psilocybin therapy, administered in conjunction with psychological support, for patients with treatment-resistant depression who have not responded to conventional treatments.
Boundless Bio
Series C in 2023
Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.
Escient Pharmaceuticals
Series C in 2022
Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.
Metagenomi
Series B in 2022
Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.
Apella is a medical technology company that uses artificial intelligence, computer vision, and sensor data from operating rooms to digitize surgical workflows. Its platform collects real-time data from in-room devices to analyze surgical procedures and provide actionable insights for process improvement, quality control, training, and real-time decision support, with the goal of improving surgical outcomes. The company was founded in 2019 and is headquartered in San Francisco.
Lark is a developer of a virtual platform focused on chronic disease prevention and management. Founded in 2011 by Julia Hu and Jeff Zira, the company is headquartered in Mountain View, California. Lark's platform leverages advanced artificial intelligence alongside human coaching and connected devices to offer real-time, personalized support and counseling. This approach aims to help users make healthier choices and effectively manage their chronic conditions. The company's programs, including those recognized by the CDC for diabetes prevention, wellness, diabetes care, and hypertension, serve approximately 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in multiple peer-reviewed journals and analyst reports.
Caresyntax
Series C in 2021
Caresyntax develops a digital surgery platform that improves patient outcomes by analyzing large volumes of data from operating rooms. Its proprietary software and AI enable OR teams to predict and enhance surgical performance, helping surgeons benchmark their care, hospital administrators optimize resources, medical device companies advance products, and insurance providers assess risk.
Turnstone Biologics
Series D in 2021
Turnstone Biologics is a clinical-stage biotechnology company focused on developing viral immunotherapies to improve cancer survival. Its lead candidate, RIVAL-01, combines three immunomodulators to stimulate immune activity and reprogram the tumor microenvironment.
CMR Surgical
Series D in 2021
Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.
NiKang Therapeutics
Series C in 2021
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.
Collective Health
Series F in 2021
Collective Health provides a cloud-based health benefits platform that unifies medical, dental, vision, pharmacy, and related programs into a single administration experience, helping employers simplify benefits, guide employees in understanding and navigating care, and manage costs and outcomes. The platform offers integrated administration of all health plans through one portal, with live concierge support and digital tools to find and manage care, and connects employees with medical, pharmacy, dental, and vision providers. Headquartered in San Francisco with offices in Chicago and Lehi, it aims to reduce the administrative burden of delivering benefits while improving member experience and overall health outcomes.
Boundless Bio
Series B in 2021
Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.
Crossover Health
Series D in 2021
Crossover Health designs and delivers workplace healthcare services for employers and employees, offering primary care and a broad range of ancillary and advanced services, including urgent and preventive care, chronic disease management, health risk assessment, health education, coaching, biometrics, physical therapy, chiropractic, acupuncture, care coordination, health analytics, and remote care. It operates as a primary care medical group that blends health management services with technology-enabled tools to create a comprehensive employee care experience. Founded in 2010 and based in California, Crossover Health serves client organizations through on-site and partner health centers across Silicon Valley and other U.S. locations, with a focus on improving access to care, enhancing member experience, and reducing healthcare costs for employers and their workforce.
Caribou Biosciences
Series C in 2021
Caribou Biosciences develops cellular engineering solutions based on CRISPR technologies, offering a gene editing platform with applications in human therapeutics, disease modeling, genomics research, and agricultural biotechnology.
Sagimet Biosciences
Venture Round in 2021
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat diseases like nonalcoholic steatohepatitis (NASH) and certain cancers. The company specializes in targeting dysfunctional metabolic pathways, with a particular expertise in fatty acid synthase (FASN) biology.
Personal Genome Diagnostics
Series C in 2021
Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.
IO Biotech
Series B in 2021
IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.
Cytrellis Biosystems
Series C in 2021
Cytrellis Biosystems, Inc. is a clinical stage medical technology company focused on designing and developing innovative devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin changes through non-surgical solutions. Its products are specifically engineered to remove sagging skin without the need for invasive procedures or scarring, thereby offering aesthetic practitioners enhanced capabilities to improve the appearance of aging skin. Cytrellis Biosystems is dedicated to advancing the field of aesthetic medicine with its cutting-edge technologies.